Aarti Drugs Balance Sheet Health
Financial Health criteria checks 5/6
Aarti Drugs has a total shareholder equity of ₹12.8B and total debt of ₹5.9B, which brings its debt-to-equity ratio to 46%. Its total assets and total liabilities are ₹24.3B and ₹11.5B respectively. Aarti Drugs's EBIT is ₹2.4B making its interest coverage ratio 7.4. It has cash and short-term investments of ₹295.6M.
Key information
46.0%
Debt to equity ratio
₹5.88b
Debt
| Interest coverage ratio | 7.4x |
| Cash | ₹295.60m |
| Equity | ₹12.78b |
| Total liabilities | ₹11.52b |
| Total assets | ₹24.30b |
Recent financial health updates
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05
Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)
Oct 11Financial Position Analysis
Short Term Liabilities: AARTIDRUGS's short term assets (₹12.6B) exceed its short term liabilities (₹7.8B).
Long Term Liabilities: AARTIDRUGS's short term assets (₹12.6B) exceed its long term liabilities (₹3.7B).
Debt to Equity History and Analysis
Debt Level: AARTIDRUGS's net debt to equity ratio (43.7%) is considered high.
Reducing Debt: AARTIDRUGS's debt to equity ratio has reduced from 77% to 46% over the past 5 years.
Debt Coverage: AARTIDRUGS's debt is well covered by operating cash flow (52.4%).
Interest Coverage: AARTIDRUGS's interest payments on its debt are well covered by EBIT (7.4x coverage).